Wesley Jongbloed
VU University Medical Center
11 Papers
3 Citations
Wesley Jongbloed is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Clusterin & Cognitive decline. The author has an hindex of 9, co-authored 11 publications.
Chat about Author
Papers
Amyloid-beta oligomer detection by ELISA in cerebrospinal fluid and brain tissue
Kim Bruggink,Wesley Jongbloed,Elisanne A.L.M. Biemans,Robert Veerhuis,Jurgen A.H.R. Claassen,H.B. Kuiperij,Marcel M. Verbeek +6 more
TL;DR: An enzyme-linked immunosorbent assay (ELISA) specific for Aβ oligomers is developed by using the same capture and (labeled) detection antibody for relatively small oligomers (10-25 kDa) and not monomers, suggesting that levels ofsmall oligomers might not be suitable as biomarkers for AD.
111
Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays.
Marta Del Campo,Wesley Jongbloed,Harry Twaalfhoven,Robert Veerhuis,Marinus A. Blankenstein,Charlotte E. Teunissen +5 more
TL;DR: A specific and detailed workflow to develop and validate new ELISA for a successful and reliable validation of novel dementia biomarkers is described and covers several critical aspects, including production, screening, and selection of specific antibodies until optimal fine-tuning of the assay.
Clusterin: An early biomarker for Alzheimer's disease?
Karin van Dijk,Wesley Jongbloed,Wilma van de Bergh,Philip Scheltens,Sandra D. Mulder,Piet Eikelenboom,Marinus A. Blankenstein,Wiesje M. van der Flier,R. Veerhuis +8 more
TL;DR: This research presents a novel and scalable approach to caring for patients with Alzheimer’s disease that combines natural selection, social support, and coaching.
2
Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer’s Disease
Wesley Jongbloed,Karin van Dijk,Sandra D. Mulder,Wilma D.J. van de Berg,Marinus A. Blankenstein,Wiesje M. van der Flier,Robert Veerhuis +6 more
TL;DR: Elevated plasma clusterin levels in MCI confer an increased risk for progression to AD, and more rapid cognitive decline, which is speculated to reflect its involvement in the earliest neurodegenerative processes associated with AD pathology.